Oregovomab

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

Retrieved on: 
Thursday, October 12, 2023
III, Partnership, HR, Oregovomab, Survival, Ovarian cancer, Carboplatin, Paclitaxel, Immune system, AU, Progression-free survival, Patient, Pharmaceutical industry, Nursing

SINGAPORE and SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc., acquiring the exclusive license to a new monoclonal antibody therapy for patients with ovarian cancer in Australia, New Zealand and in select Southeast Asian countries.

Key Points: 
  • Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam
    SINGAPORE and SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc., acquiring the exclusive license to a new monoclonal antibody therapy for patients with ovarian cancer in Australia, New Zealand and in select Southeast Asian countries.
  • Announcing the partnership, ST Chief Executive Officer Carlo Montagner said he was pleased CanariaBio had selected ST as a partner for this highly promising therapy.
  • "ST has a portfolio of anti-cancer therapies targeting multiple solid tumours with the exception of ovarian cancer, and now oregovomab becomes our first ovarian cancer agent," Mr Montagner said.
  • At CanariaBio, we've always believed in the transformative power of partnerships, and teaming up with ST reinforces this belief."

CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region

Retrieved on: 
Tuesday, October 10, 2023
Patient, HR, Paclitaxel, Progression-free survival, Carboplatin, Oregovomab, Film industry

SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa (MENA) region.

Key Points: 
  • SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa (MENA) region.
  • "We are thrilled to partner with Hikma, a company with a strong presence in the MENA region and a proven track record of successful collaborations," said Michael Na, CEO of CanariaBio.
  • Oregovomab is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer in the phase 3 FLORA-5 trial.
  • In Phase 2, the addition of oregovomab yielded a median progression-free survival of 41.8 months compared with 12.2 months with standard chemotherapy (HR, 0.46, P=0.0027).

CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination with Niraparib in the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Tuesday, August 8, 2023
GSK, Ovarian cancer, KOSDAQ, Niraparib, Immunization, Recurrence, PARP, Patient, PFS, ADP, Pharmaceutical industry, Oregovomab

SEOUL, S.KOREA, Aug 8, 2023 - (ACN Newswire) - CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer.

Key Points: 
  • SEOUL, S.KOREA, Aug 8, 2023 - (ACN Newswire) - CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer.
  • This trial, known as FLORA-4 (NCT05335993), is being conducted by CanariaBio, with GSK providing clinical trial supply of niraparib.
  • The study will assess the immunological and clinical activity, early humoral response, and disease control rate of concomitant Oregovomab and daily oral niraparib.
  • This will be a preliminary investigation of the interaction of indirect immunization with Oregovomab and concomitant niraparib therapy and the immune modulatory effects associated with PARP inhibition.

OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

Retrieved on: 
Tuesday, March 28, 2023
Tao, Therapy, Marketing, European Medicines Agency, Cancer, Woman, Oregovomab, Immunotherapy, PFS, OEP, Sale, EMA, CDMO, The Company, Patient, Mab, Ovarian cancer, FDA, Phase, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, Disease, Pharmaceutical industry

OEP also agreed to purchase oregovomab from OncoVent at a price equal to an agreed percentage to the average sale price of oregovomab in Taiwan.

Key Points: 
  • OEP also agreed to purchase oregovomab from OncoVent at a price equal to an agreed percentage to the average sale price of oregovomab in Taiwan.
  • In addition, OncoVent granted OEP the right of first refusal for the exclusive sales, marketing, and distribution right in Hong Kong and Macau.
  • Oregovomab has obtained Orphan Drug Designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • The first patient in a Phase III clinical trial of oregovomab was dosed in the U.S. in 2020.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, View, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Multimedia, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, September 1, 2021
SingHealth, Oregovomab, Terminology, Ovarian cancer, Drug combination, Korea University College of Science, PD-1, KOREA, Paclitaxel, Korean Government Scholarship Program, Cancer, Carboplatin, Korea University College of Medicine, Doxorubicin, Survival, HER2/neu, Bevacizumab, MUC1, PSA, Disease, Platinum, Gynecologic Oncology (journal), Death, TSX Venture Exchange, Antibody, Clinical trial, Overalls, Safety, Risk, Cancer immunology, Patient, Immunoglobulin G, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Toxicity, Immunization, Hospital, Nivolumab, Pharmaceutical industry

The study will establish the safety and compatibility of the combination of these agents as possible approaches in patient management(ClinicalTrials.gov Identifier: NCT04938583).

Key Points: 
  • The study will establish the safety and compatibility of the combination of these agents as possible approaches in patient management(ClinicalTrials.gov Identifier: NCT04938583).
  • The second study(ORION-02), led by Clinical Assistant Professor Jack Chan, is being conducted at a single centre in Singapore (National Cancer Centre Singapore).
  • OncoQuest has completed a Phase II study using oregovomab in combination with a TLR-3 agonist (Hiltonol) in the recurrent ovarian cancer setting (ClinicalTrials.gov Identifier: NCT03162562).
  • OncoQuest is also in the process of initiating a clinical trial using oregovomab with niraparib in the recurrent ovarian cancer setting.